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Abstract
Background: Identifying causes of alemtuzumab induced respiratory symptoms in Multiple Sclerosis (MS) patients
is crucial.
Case presentation: We report a case of diffuse alveolar damage (DAD) in a patient with MS after the first course of
alemtuzumab treatment. A 42-year-old female developed progressive non-productive cough and exertional
dyspnea 2 months after alemtuzumab treatment. DAD was diagnosed histopathologically by lung biopsy. The
patient recovered completely, alemtuzumab was not continued.
Conclusions: Our case highlights another pathomechanism for non-infective lung-disorders in alemtuzumab
treated MS patients. DAD is a potential, albeit rare side effect of alemtuzumab, broadening the spectrum of non-
infective lung disorders that should be considered in the diagnostic work-up.
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Background
Alemtuzumab is a humanized monoclonal antibody,
which targets the surface molecule CD52 on immune
cells (T- and B-cells, monocytes, dendritic cells and
thymocytes) and leads to a rapid and significant de-
pletion of those cell types [1]. Well-known side ef-
fects include an increased infection rate including
respiratory tract infections and secondary auto-
immune reactions mainly consisting of thyroid disor-
ders, immune thrombocytopenia, anti-glomerular
basement membrane (GBM) disease and membran-
ous glomerulonephritis, which may occur after years
of first treatment. Since its approval by the European
Medicines Agency (EMA) in 2013, non-infective re-
spiratory tract side effects causing dyspnea have been
reported in patients treated with alemtuzumab in-
cluding diffuse alveolar hemorrhage [2], pneumonitis
[3], anti-GBM antibody disease [4] and acute
respiratory distress syndrome (ARDS) [5]. Five cases
of diffuse alveolar damage (DAD) associated with
alemtuzumab have been reported to VigiBase©, the
World Health Organization’s international database
for suspected adverse drug reactions [6], without
providing further details on treated disorders or
other potentially confounding factors. Our report de-
scribes a patient with DAD after alemtuzumab treat-
ment for MS. Compared to cases of alemtuzumab
associated DAD published so far [6], here we present
detailed clinical data and results of apparative diag-
nostics, furthermore histological findings that have
so far not been reported in ARDS associated with
alemtuzumab treatment [5].
Case presentation
A 42-year-old, non-smoking female with highly active
relapsing remitting multiple sclerosis (MS) and no con-
comitant diseases was first diagnosed in 2008. Interferon
beta (IFNB)-1a intramuscularly, injected 03/2008, was
stopped due to a suspected allergic reaction, intradermal
testing for IFNB-1a and -1b could not exclude an
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allergic reaction. Glatiramer acetate had to be with-
drawn after 4 months (07/2008–11/2008) for elevated
liver enzymes. Due to high disease activity natalizu-
mab was initiated in 2009 and stopped in 2012 be-
cause of JC-virus antibody positivity, hereafter the
patient refused further immunotherapies. After a se-
vere relapse resolving only after plasma exchange
(PLEX), treatment with fingolimod was initiated, but
stopped after 4 months due to another severe relapse
requiring treatment with glucocorticosteroids and
again PLEX. After 2 further relapses and magnetic
resonance imaging (MRI) activity in 2013, treatment
with alemtuzumab was decided.
In January 2014 alemtuzumab (12 mg daily) was ap-
plied over 5 days, methylprednisolone 1 g, dimetin-
dene, ranitidine, acyclovir and ibuprofen were given
as concomitant medication. Except of fatigue and a
mild bradycardia, infusions were well-tolerated. After
2 months, progressive non-productive cough, exer-
tional dyspnea and general exhaustion developed. C-
reactive protein and leucocytes were normal. Com-
puted tomography- (CT-) scan of the lung showed
atelectasis in both lower lobes without evidence of
atypical pneumonia. Lung function tests showed a
high-grade restriction in diffusion capacity (diffusing
capacity of the lung for carbon monoxide (DLCO) 45%
of normal) as well as a respiratory alkalosis (pH 7.46,
pCO2 34.3 mmHg), a respiratory partial insufficiency
in ergospirometry (decrease of pO2 from 89 mmHg to
78 mmHg and increase of lactate from 1.0 to 5.5
mmol/l during exercise with 150 watt) and a low-
grade restrictive lung disease (vital capacity (VC):
2.75 l, reference: ≥ 3.70 l) without obstructive impair-
ment (FEV1 (forced expiratory volume in 1 s)/VC:
88.7%, reference: ≥ 80.9%). Bronchoalveolar lavage re-
vealed a moderately active inflammation and a re-
duced CD4/CD8-ratio (0,67; reference ≈ 2) consistent
with an extrinsic allergic alveolitis or a damage of
pneumocytes due to drug toxicity. However, an ex-
trinsic allergic alveolitis seemed unlikely because of
negative specific IgG antibodies. The Prick test and
Methacholin provocation test, suggesting an allergic
reaction or a hyperreagibility of the bronchial system,
were negative. Histopathologically, hyperplasia of al-
veolar pneumocytes and remnants of hyaline mem-
branes consistent with a diffuse alveolar damage were
found in a transbronchial lung biopsy (Fig. 1). There
was no evidence for an infectious agent. Renal func-
tion, urine test and anti-GBM antibodies indicating
an alemtuzumab-associated Goodpasture syndrome,
were unremarkable. Platelets and thyroid function
were normal, thyroid antibodies were not determined.
Based on these results, a diffuse alveolar damage
(DAD) related to alemtuzumab drug toxicity was
diagnosed. Respiratory symptoms regressed over few
months, no corticosteroids were given. Diffusion cap-
acity in December 2014 and December 2015 had con-
stantly improved (single-breath-methode, DLCO 71,5 and
81% respectively of normal). Blood gas analysis and lung
function tests were normal lately.
Due to the increased risk for recurrent toxicity,
alemtuzumab was not continued and treatment
switched to rituximab (off-label) in January 2015. MS
clinical course and MRI controls have been stable
since 2014. The disease course and treatments are
shown in Fig. 2. Written informed consent for patient
information and images to be published was provided
by the patient.
Discussion and conclusions
Over the last years, reports of serious adverse events also
affecting the lungs have prompted the EMA to amend
the label for alemtuzumab [7]. More recently, further
cases of treatment-induced lung injury have broadened
the spectrum of non-infective respiratory disorders after
alemtuzumab treatment in MS [5]. To our knowledge,
Fig. 1 Lung biopsy, hematoxylin and eosin stain: a arrows indicate
activated pneumocytes, b arrows indicate residual
hyaline membranes
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our case is the first report of DAD in MS after alem-
tuzumab treatment examined histologically. ARDS as
a clinical correlate of DAD after alemtuzumab treat-
ment in MS has recently been published, but lung bi-
opsy is not reported [5]. DAD is characterized by
dyspnea and dry cough progressing over a period of
days or weeks. High-resolution CT typically shows a
combination of ground-glass opacity and consolida-
tion involving predominantly dependent regions or
distributed more randomly throughout both lungs [8].
DAD can be induced by infections, inhalational injur-
ies, connective tissue diseases and also drugs [9]. It is
the most commonly reported histologic manifestation
of drug toxicity usually developing after a few weeks
or months [8]. The mortality rate in DAD has been
reported to be high. In a series of 58 patients with
DAD diagnosed by surgical lung biopsy over a 7-year
period, 60% were immunocompromised. In this study,
the most common cause of DAD were infections
(22%), drugs were found to be causal in 10% of cases.
The overall hospital mortality rate associated with
DAD was 53%, in the group of drug induced DAD 1
of 6 patients died [9]. In our case, respiratory symp-
toms occurred 2 months after the alemtuzumab cycle,
according to the latency known from other drugs.
Fortunately, the patient reported gradually recovered
over months without subjective residual symptoms.
Apart from atelectasis, the initial CT scan revealed no
abnormal findings indicating a milder lung involve-
ment and possibly explaining a less severe disease
course.
Various pathological phenomena underlying DAD
have been reported, among them endothelial and al-
veolar cell injury leading to fluid and cellular exsuda-
tion with hyaline membranes and edema [10]. The
mechanism underlying alemtuzumab induced DAD is
unknown. In diffuse alveolar hemorrhage after alem-
tuzumab treatment, it has been speculated that alem-
tuzumab induced effector mechanisms lead to acute
inflammation that may damage membranes and cells
not expressing CD52 [2].
Our report shows that DAD is a potential, albeit rare
side effect of alemtuzumab, broadening the spectrum of
non-infective lung disorders that should be considered
in the diagnostic work-up.
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